BioMedNewsBreaks — Octane Selects IBN as Official Media Partner for Upcoming Medical Innovation Forum

Octane, a convening organization of the Southern California technology and medical technology business ecosystem, is partnering with IBN (“InvestorBrandNetwork”), a pioneering corporate communications firm and content distributor, to provide key communications and coverage of Octane’s Medical Innovation Forum. According to the announcement, IBN will serve as Official Media Partner for the event, with IBN’s InvestorWire serving as the Official NewsWire. The two-day forum is slated for Oct. 25–26, 2023, in Irvine, California. Octane is committed to create and support a thriving business ecosystem in Southern California by fostering the growth of tech and medtech ventures; the organization has a goal of generating some 55,000 high-paying technology jobs in the region by 2030. The Medical Innovation Forum will focus on “entrepreneurial intelligence” (“EI”) within the medical devices, pharmaceutical and healthcare sectors and will feature discussions on a diverse range of topics designed to enhance business success and facilitating interactions between entrepreneurs and potential investors. “We are thrilled to extend our multiyear collaboration with IBN,” said Octane director of marketing Natalie Matsumoto in the press release. “Together, we aim to magnify the reach of the forum’s invaluable insights and groundbreaking discussions, ensuring that our vision of advancing healthcare through entrepreneurial intelligence reaches a wider audience.”

To find out more about the forum, visit https://ibn.fm/Wa25X

To view the full press release, visit https://ibn.fm/3wCBY

About Octane

Octane is a convening organization of the Southern California technology and medical technology business ecosystem. The company connects people, resources and capital. Octane is committed to help create 55,000-plus high-paying technology jobs in Southern California by 2030 through our accelerator LaunchPad SBDC as well as our platform Octane Capital & Growth. In addition, Octane hosts dozens of programs throughout the year and has direct access to capital and partners. The company believes that action focused locally has impact globally. For more information about the organization, visit www.OctaneOC.org.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Two Years of Clinical Milestones Across Oncology and Rare Disease Programs 

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, announced…

3 days ago

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Expands IP Portfolio with New U.S. Patent Filings

HealthLynked (OTCQB: HLYK), a leader in patient-centric healthcare technology, announced the submission of two new…

3 days ago

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in MarketScreener Editorial on Targeted AI Applications

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for…

4 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl

Nutriband (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, highlighted…

5 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Engages IBN to Lead Corporate Communications

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy and targeted treatments for…

5 days ago

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast 

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company developing targeted cancer therapies with its proprietary…

5 days ago